asked the Secretary of State for Social Services how many of the manufacturing sites used by Harris Pharmaceuticals Ltd. for the production of generic medicines sold to the National Health Service were subject to inspection by the United Kingdom Medicines Inspectorate in each of the last three years; and when Harris Pharmaceuticals Ltd's manufacturing sites in South Africa were last inspected by the United Kingdom Medicines Inspectorate.
The manufacturing sites used by Harris Pharmaceuticals Ltd. for products for which it holds United Kingdom product licences are largely covered by multilateral agreements which provide for inspection reports to be supplied to the United Kingdom medicines inspectorate by the licensing authority of the country concerned. The remainder have been inspected by the
|Income (£)||Bad debts and claims abandoned (£)|
|Health Districts||Section 58||Section 65||Section 66||Section 65||Section 66|
|North West Durham||—||28,329||7,550||6||429|
|South West Durham||—||9,617||5,577||—||413|
United Kingdom medicines inspectorate or are scheduled for a visit within the next 12 months. All South African manufacturing sites named as possible sources of supply for Harris Pharmaceuticals Ltd. were inspected by United Kingdom medicines inspectors in the last 16 months. The frequency of inspection is a matter for the licensing authority and details of dates of individual inspections are not normally disclosed.